Pieris Pharma (PIRS) Reports Dosing of First Patient in Phase I Trial for Fully Proprietary Lead IO Program, PRS-343
Tweet Send to a Friend
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS) today announced that the first patient has been dosed in the Company's Phase I clinical ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
